BioSpace News Archive

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2022.

Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 and to provide a corporate update.

New secondary analysis from Eli Lilly and Company’s Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code for Byfavo® 1 (remimazolam for injection).

Lannett Company, Inc. (OTCMKTS: LCIN) (the “Company” or “Lannett”) today announced that, together with certain of its subsidiaries (collectively with the Company, as applicable, the “Company Parties”), it has entered into a Restructuring Support Agreement (the “RSA”) with holders of more than 80% of its 7.750% senior secured notes due 2026.

NovaBay Pharmaceuticals Fulfills $1 Million Order for NeutroPhase ® Skin and Wound Cleanser for China Pioneer Pharma Holdings

Immatics N.V. (NASDAQ: IMTX, “Immatics”) today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy (TCR-T) candidate from their ongoing collaboration.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report first quarter 2023 financial results prior to the market open on Monday, May 15, 2023.

TFF Pharmaceuticals, Inc. announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective Biosystems program to develop next-generation countermeasures for military and healthcare personnel.